Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0001493152-26-000967 0001279191 XXXXXXXX LIVE 9 Common Stock, Par Value $0.0001 Per Share. 01/29/2026 false 0001853816 249845504 Dermata Therapeutics, Inc. 3525 Del Mar Heights Rd., #322 San Diego CA 92130 Gerald T. Proehl (973) 701-2431 President and Chief Executive Officer, 3525 Del Mar Heights Rd., #322 San Diego CA 92130 0001279191 N PROEHL GERALD T PF N X1 694576.00 0.00 694576.00 0.00 694576.00 N 19.6 IN See Item 5 for additional information. Common Stock, Par Value $0.0001 Per Share. Dermata Therapeutics, Inc. 3525 Del Mar Heights Rd., #322 San Diego CA 92130 This Amendment No. 9 (this "Amendment") amends and supplements the Schedule 13D filed on behalf of the Reporting Persons with the Securities and Exchange Commission on August 27, 2021, as amended on April 25, 2022, January 13, 2023, March 30, 2023, January 23, 2025, February 13, 2025, April 3, 2025, April 7, 2025, and January 8, 2026 (collectively, the "Schedule 13D"). Except as specifically provided herein, this Amendment does not modify or amend any of the information previously reported in the Schedule 13D. Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13D. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. The information contained in rows 7, 8, 9, 10, 11 and 13 of the cover pages of this Schedule 13D and the information set forth in or incorporated by reference in Item 2 and Item 3 of the Schedule 13D is hereby incorporated by reference in its entirety into this Item 5. As of the date hereof, Mr. Proehl may be deemed to beneficially own an aggregate of 694,576 shares of Common Stock reported herein as follows: (i) 24 shares of Common Stock and stock options to purchase 1,763 shares of Common Stock held directly by Mr. Proehl; (ii) 79,950 shares of Common Stock and 11 shares of Common Stock underlying warrants that are exercisable within sixty (60) days of the date hereof held by Proehl Investment Ventures LLC ("PIV"); and (iii) 612,828 shares of Common Stock held in the aggregate by certain trusts (the "Trusts") for which Mr. Proehl is trustee. Mr. Proehl's reported ownership excludes (i) 41,070 shares of Common Stock underlying stock options held by Mr. Proehl that will not vest as to such shares of Common Stock within sixty (60) days of the date hereof; and (ii) 78,740 shares of Common Stock underlying warrants that are not exercisable within sixty (60) days of the date hereof. The warrants reported in (ii) above are not exercisable until the Issuer obtains stockholder approval of the transaction in which such warrants were issued. As a result of the foregoing, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, Mr. Proehl may be deemed to beneficially own 19.6% of the Common Stock of the Issuer outstanding as of the date hereof (based on 3,549,393 shares of Common Stock outstanding as of January 29, 2026 based on information obtained from the Issuer). As of the date hereof, Mr. Proehl may be deemed to be the beneficial owner of an aggregate of 694,576 shares of Common stock, all of which he has sole voting and dispositive power. Since Amendment No. 8 to this Schedule 13D (filed on January 8, 2026), there were no purchases or sales of shares of Common Stock, or securities convertible into or exchangeable for shares of Common Stock, by the Reporting Person or any person or entity for which the Reporting Person possess voting or dispositive control over the securities thereof. None. None. PROEHL GERALD T /s/ Gerald T. Proehl Gerald T. Proehl 02/02/2026